Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 55 results for cervical cancer

  1. Screening: cervical screening (25 to 49 years) (IND176)

    This indicator covers the proportion of patients eligible for cervical screening and aged 25 to 49 years at end of period reported whose notes record that an adequate cervical screening test has been performed in the previous 3.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM154

  2. Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690

    Awaiting development [GID-TA11073] Expected publication date: TBC

  3. Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

    In development [GID-TA10620] Expected publication date: TBC

  4. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

  5. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

    This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.

  6. Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)

    Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making

  7. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  8. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  9. HIV testing: encouraging uptake (QS157)

    This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.

  10. High dose rate brachytherapy for carcinoma of the cervix (IPG160)

    Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.

  11. Physical health of people in prisons (QS156)

    This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.

  12. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

  13. Laparoscopic techniques for hysterectomy (IPG239)

    Evidence-based recommendations on laparoscopic techniques for hysterectomy. This involves surgically removing the uterus using special instruments through small cuts in the abdomen (keyhole surgery).

  14. Ovarian cancer (QS18)

    This quality standard covers the recognition and initial management of ovarian cancer. It describes high-quality care in priority areas for improvement.

  15. The committee recommended that further research is needed to better understand the natural history of low-volume cervical intraepithelial neoplasia (CIN) 2 lesions.

    research is needed to better understand the natural history of low-volume cervical intraepithelial neoplasia (CIN) 2 lesions. Any...